PCSK9 Inhibitors [PCSK9 inhibitory]

topical
249
Terms

inhibitory PCSK9
kardiovaskulární inhibitory PCSK9
kardiovaskulární PCSK9 inhibitory

 

PCSK9 Inhibitors Cardiovascular
PCSK9 Inhibitors, Cardiovascular

Definition

Agents that inhibit Proprotein Convertase Subtilisin/Kexin Type 9 (see PROPROTEIN CONVERTASE 9 (PCSK9)), an enzyme that plays an important role in the degradation of the LDL receptors. It favors LDL catabolism and reduces plasma LDL-cholesterol (LDL_C) level.

DUI
D000091362 MeSH Browser
CUI
M000748765
Previous indexing
Anticholesteremic Agents (2018-2021)
History note
2022
Public note
2022

D Chemicals and Drugs
D27.505.519.186 Antimetabolites 120
D27.505.519.186.071 Hypolipidemic Agents 1 641
D27.505.519.186.071.202 Anticholesteremic Agents 416
D27.505.519.186.071.202.370 Hydroxymethylglutaryl-CoA Reductase Inhibitors 1 856
D27.505.519.186.071.202.685 PCSK9 Inhibitors 249
D27.505.519.389 Enzyme Inhibitors 883
D27.505.519.389.745 Protease Inhibitors 274
D27.505.519.389.745.800 Serine Proteinase Inhibitors 49
D27.505.519.389.745.800.449 Antithrombins 253
D27.505.519.389.745.800.506 PCSK9 Inhibitors 249
D27.505.519.389.745.800.562 Serine Peptidase Inhibitors, Kazal Type
D27.505.519.389.745.800.675 Serpins 41
D27.505.519.389.745.800.900 Trypsin Inhibitors 122
D27.505.954 Therapeutic Uses 62
D27.505.954.557 Lipid Regulating Agents 8
D27.505.954.557.500 Hypolipidemic Agents 1 641
D27.505.954.557.500.202 Anticholesteremic Agents 416
D27.505.954.557.500.202.370 Hydroxymethylglutaryl-CoA Reductase Inhibitors 1 856
D27.505.954.557.500.202.685 PCSK9 Inhibitors 249